The abstract is read at the publisher; the summary is JClub's.
Donor-derived hexaviral-specific T cells targeting CMV, AdV, EBV, BKV, HPIV3, and HHV6 were tolerated in 14 post-HCT patients, with 8/8 evaluable showing partial or complete responses at 3 months.
- Why it matters: Viral reactivation is common after hematopoietic stem cell transplant, and multivirus T cell approaches are needed to control multiple infections while limiting treatment-related toxicity.
- What they did: The study infused the hexaviral-specific T cell product into 5 adults and 9 pediatric patients, then assessed toxicities and viral responses at 3 months; single-cell gene expression profiled the infused T cells and recipient blood (n=4).
- The result: After infusion, recipient peripheral blood shifted from a naïve/indistinct T cell profile to predominantly memory T cell populations after a median of 70 days, supporting potential prevention and treatment of multiple viruses post-HCT.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.